CELL INTELLIGENCE · 肿瘤细胞治疗研究

用于胆管癌的小鼠 TIL（肿瘤浸润淋巴细胞）治疗模型的建立

Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma.

通过化疗和 CTLA-4 阻断重编程肝内胆管癌免疫微环境增强抗 PD-1 治疗

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy.

转移性胆管癌患者 TIL（肿瘤浸润淋巴细胞）对 FGFR2 融合的特异性识别

Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma.

这一发现表明，可以从部分转移性 ICC 患者中分离出 FGFR2 融合反应性 TIL，因此为未来在癌症患者中探索靶向 FGFR2 融合的 T 细胞疗法提供了依据。此外，它为将此类工作扩展到以致癌基因融合为特征的其他类型实体瘤增强了依据。

T 细胞激动剂治疗增强 MEK 抑制的环境依赖性免疫调节效应

Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy.